The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?

Renal cell carcinoma (RCC) is an increasingly common malignancy that can progress to metastatic renal cell carcinoma (mRCC) in approximately one-third of RCC patients. The 5-year survival rate for mRCC is abysmally low, and, at the present time, there are sparingly few if any effective treatments. C...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Alessandra Cinque, Anna Capasso, Riccardo Vago, Michael W Lee, Matteo Floris, Francesco Trevisani
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-12-01
coleção:	Biomedicines
Assuntos:	liquid biopsy renal cell carcinoma target therapies biomarkers circulating tumor cells circulating tumor DNA
Acesso em linha:	https://www.mdpi.com/2227-9059/10/1/90
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!